Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...

Johnson & Johnson’s (J&J) Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults ...

Almirall has announced that it will be hosting the 16th edition of its Skin Academy, a conference that encourages ...

It is becoming an essential factor not only in the successful integration of medicines into clinical practice but also in ...

ABPI's recent update permits QR codes in printed pharmaceutical materials for prescribing information. By ensuring visibility ...

Pharma companies must balance HCP access and MHRA/ABPI compliance by preventing public search indexing of promotional ...

As we approach 2025, healthcare and life sciences SMEs face an increasingly digital world. A seamless, mobile-friendly ...

Life sciences digital agency Genetic Digital has launched Pi 360, a cutting-edge web application designed to help ...

Sanofi has announced that it will be broadening its immunology pipeline by acquiring Dren Bio’s phase 1 CD20-directed ...

AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...

Novartis also shared results from the open-label phase 3b STRENGTH study of OAV101 IT in SMA patients aged two to less than 18 years who had discontinued treatment with nusinersen or risdiplam, which ...

For example, developing a drug nowadays takes eight to ten years and costs over $2bn, yet less than 10% of clinical ...